EUCAST Steering Committee Meeting
Munich, Germany, 3-4 April 2007

Attending

Dr Derek F.J. Brown  DB  Scientific Secretary  United Kingdom
Dr Rafael Canton  RC  Clinical Data Co-ordinator  Spain
Prof Waleria Hryniewicz  WH  EUCAST  Poland
Prof Gunnar Kahlmeter  GK  Chairperson  Sweden
Prof Alasdair P. MacGowan  AM  BSAC  United Kingdom
Dr Johan W. Mouton  JM  CRG  The Netherlands
Prof Inga Odenholt  IO  SRGA  Sweden
Prof Arne Rodloff  AR  DIN  Germany
Prof Claude-James Soussy  CS  SFM  France
Dr Martin Steinbakk  MS  NWGA  Norway

Apologies

Dr Fred Goldsein  FG  SFM  France
Prof Pietro Varaldo  PV  EUCAST  Italy

1 Chairman’s welcome  CS represented SFM in place of FG.

2 Minutes of meeting of 30-31 January 2007  The minutes were accepted as a correct record.

3 Matters arising from minutes of 30-31 January 2007
Declarations of interests will be returned.
Aminoglycoside and glycopeptide technical notes and rationale documents will be reformatted.
Additional MIC distribution data for macrolides will be collected.
Rationale documents for miscellaneous agents not in major groups are being developed.
There has been further correspondence on definitions of breakpoints and epidemiological cut-offs.
Ciprofloxacin breakpoints for Pseudomonas spp. may be reviewed in the future.
The company will provide further information on a new glycopeptide when submitted to the EMEA.
The new quinolone and fluconazole rationale documents have been completed.
The BSAC have prepared a rationale document for temocillin.
Changes to the AFST document on microdilution susceptibility testing were proposed.
A review of trimethoprim for enterococci has been prepared for the SRGA.
45° study data for penicillin, ampicillin and amoxycillin MICs for S. pneumoniae have been provided.
Expert groups will be consulted on proposed penicillin and macrolide breakpoints as part of the
general consultation. The current draft breakpoints were redistributed to the Steering Committee.
No mecillinam MIC distributions are available.

4 New agents  Current status was reviewed

5 Ciprofloxacin rationale document  The updated document was reviewed and changes agreed.
<table>
<thead>
<tr>
<th></th>
<th><strong>Rationale documents</strong></th>
<th>Agreed to update to the revised format all rationale documents currently being prepared.</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td><strong>Penicillin breakpoints</strong></td>
<td>Draft tables were reviewed and modifications were agreed. Following checks by the Steering Committee the draft breakpoints will be released for general comment.</td>
</tr>
<tr>
<td>8</td>
<td><strong>Macrolide breakpoints</strong></td>
<td>Draft tables were reviewed and modifications were agreed. Following checks by the Steering Committee the draft breakpoints will be released for general comment.</td>
</tr>
<tr>
<td>9</td>
<td><strong>Miscellaneous agents</strong></td>
<td>Discussions of breakpoints were started.</td>
</tr>
<tr>
<td>10</td>
<td><strong>Expert rules subcommittee</strong></td>
<td>Comments received from the email consultation with national committee members had been collated and would be dealt with before release of a second draft for wider consultation.</td>
</tr>
<tr>
<td>11</td>
<td><strong>EMEA</strong></td>
<td>The EMEA-EUCAST SOP is being updated.</td>
</tr>
<tr>
<td>12</td>
<td><strong>ECDC</strong></td>
<td>The ECDC has agreed to continue the EU part of the funding, but the EUCAST activity will go to tender.</td>
</tr>
<tr>
<td>13</td>
<td><strong>AFST subcommittee</strong></td>
<td>The subcommittee structure, with a Steering Committee, has been approved by the full subcommittee and the development of breakpoints for yeasts will continue.</td>
</tr>
<tr>
<td>14</td>
<td><strong>ISO/CEN</strong></td>
<td>The broth microdilution international standard method is available from ISO in Switzerland or from CLSI (note difference in price from the two sources).</td>
</tr>
<tr>
<td>15</td>
<td><strong>CLSI</strong></td>
<td>Problems with the relationship between CLSI and FDA are apparently yet to be resolved. An alternative group, BIOCAST, has been set up to recommend updated breakpoints where they feel appropriate.</td>
</tr>
<tr>
<td>16</td>
<td><strong>Implementation of EUCAST breakpoints</strong></td>
<td>Promotion of EUCAST breakpoints, implementation in automated systems and a possible disc diffusion method were discussed.</td>
</tr>
<tr>
<td>17</td>
<td><strong>ECCMID April 2008, Barcelona</strong></td>
<td>A symposium on EUCAST breakpoints will be offered. A workshop will also be considered.</td>
</tr>
<tr>
<td>18</td>
<td><strong>Any other business</strong></td>
<td>A EUCAST anaerobe subcommittee will be set up to indicate what agents require breakpoints and what is the clinical evidence related to the agents.</td>
</tr>
</tbody>
</table>
| 19 | **Next meetings** | 14-15 June 2007 Copenhagen  
6-7 September 2007 Berlin  
19-20 November 2007 Paris  
28-29 January 2008  
22-23 April 2008 Barcelona (ECCMID)  
12-13 June 2008  
8-9 September 2008  
24-25 November 2008 |

Ratified summary of minutes of meeting 3-4 April 2007. Prepared by DB, GK and RC